Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This study is monitoring patients treated with OTQ923, an investigational drug product of ex vivo genome-edited autologous hematopoietic stem and progenitor cells (HSPCs) that induces fetal hemoglobin (HbF) production, for a total of 15 years following infusion to monitor long-term safety and efficacy.
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients must have received gene therapy treatment from the parent treatment protocol (CADPT03A12101).
2. Patients must provide informed consent prior to their entry into this study.
You may not be if
1\. Completion of less than 1 year of safety follow-up in the treatment protocol (CADPT03A12101).
Clareo Health | Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
